Notice of Changes in Directors and Executive Officers | ASKA Pharmaceutical Holdings Co.,Ltd. (4886) timely disclosure

Worth reading

50Recurring

0–100. This measures how worthwhile something is to read, not how good or bad the company is.

Direction

Neutral

Direction inferred from the company’s description.

Scale

—

Displayed only when the document provides numerical figures.

Wording

Conditional

How definitive the wording is.

Who is moving to which position

Resolved 11 May 2026 (changes informally decided)

Incoming appointee

1 item

Scheduled Appointment Date24 June 2026 (the appointments of directors are conditional on approval at the 5th Annual General Meeting of Shareholders. The appointment of the executive officer is scheduled to be resolved at a Board of Directors meeting after the meeting.)

James C. Feliciano (ジェームス･フェリシアーノ), Gunji Kunihiro (軍司国弘), Kimura Takao (木村高男), Yamashita Koki (山下功起), Nishino Takeshi (西野武)

Previous positionJames C. Feliciano (ジェームス･フェリシアーノ): President of 3C Advisors GK; Representative Director and President of 株式会社 Surzen Biotherapeutics. Gunji Kunihiro (軍司国弘): Statutory auditor. Kimura Takao (木村高男): Statutory auditor. Yamashita Koki (山下功起): Statutory auditor. Nishino Takeshi (西野武): -

New positionJames C. Feliciano (ジェームス･フェリシアーノ): Director (Outside Director). Gunji Kunihiro (軍司国弘): Director and Audit and Supervisory Committee Member. Kimura Takao (木村高男): Director and Audit and Supervisory Committee Member. Yamashita Koki (山下功起): Director and Audit and Supervisory Committee Member. Nishino Takeshi (西野武): Substitute Director and Audit and Supervisory Committee Member.

生年月日 James C. Feliciano (ジェームス･フェリシアーノ): 22 September 1969. Gunji Kunihiro (軍司国弘), Kimura Takao (木村高男), Yamashita Koki (山下功起), Nishino Takeshi (西野武): Not disclosed

Departing officer

1 item

Date of departureChiku Kazuhiro (知久一博): At the conclusion of the 5th Annual General Meeting of Shareholders scheduled for 24 June 2026. Saito Junichi (齋藤淳一): Scheduled to retire at the Board of Directors meeting to be held after the conclusion of the 5th Annual General Meeting of Shareholders scheduled for 24 June 2026.

Chiku Kazuhiro (知久一博), Saito Junichi (齋藤淳一)Next role stated

Former PositionChiku Kazuhiro (知久一博): Statutory auditor. Saito Junichi (齋藤淳一): Executive officer (Director of 株式会社あすか製薬メディカル)

New positionChiku Kazuhiro (知久一博): Not disclosed. Saito Junichi (齋藤淳一): Retired

“Next role stated” means the document names the position the person holds after stepping down. It does not necessarily mean they are leaving the company.

Whether the incumbent will remain in office (whether they will retain their position)

Chiku Kazuhiro (知久一博): Will not remain on the Board of Directors. Saito Junichi (齋藤淳一): Will not remain on the Board of Directors

Directors after the change13Number

Shareholders’ meeting approvalYes. Changes in directors, including Audit and Supervisory Committee Members, are scheduled to be submitted as company proposals at the 5th Annual General Meeting of Shareholders scheduled for 24 June 2026.

Change in Corporate Governance Structure

The company plans to abolish the statutory auditor system and transition to a structure with directors who are Audit and Supervisory Committee Members.

Who is moving to which position
Item	Details
Resolution date	11 May 2026 (changes informally decided)
Scheduled Appointment Date	24 June 2026 (the appointments of directors are conditional on approval at the 5th Annual General Meeting of Shareholders. The appointment of the executive officer is scheduled to be resolved at a Board of Directors meeting after the meeting.)
Date of departure	Chiku Kazuhiro (知久一博): At the conclusion of the 5th Annual General Meeting of Shareholders scheduled for 24 June 2026. Saito Junichi (齋藤淳一): Scheduled to retire at the Board of Directors meeting to be held after the conclusion of the 5th Annual General Meeting of Shareholders scheduled for 24 June 2026.
Name of appointee	James C. Feliciano (ジェームス･フェリシアーノ), Gunji Kunihiro (軍司国弘), Kimura Takao (木村高男), Yamashita Koki (山下功起), Nishino Takeshi (西野武)
Appointee's new position	James C. Feliciano (ジェームス･フェリシアーノ): Director (Outside Director). Gunji Kunihiro (軍司国弘): Director and Audit and Supervisory Committee Member. Kimura Takao (木村高男): Director and Audit and Supervisory Committee Member. Yamashita Koki (山下功起): Director and Audit and Supervisory Committee Member. Nishino Takeshi (西野武): Substitute Director and Audit and Supervisory Committee Member.
Appointee's previous position	James C. Feliciano (ジェームス･フェリシアーノ): President of 3C Advisors GK; Representative Director and President of 株式会社 Surzen Biotherapeutics. Gunji Kunihiro (軍司国弘): Statutory auditor. Kimura Takao (木村高男): Statutory auditor. Yamashita Koki (山下功起): Statutory auditor. Nishino Takeshi (西野武): -
Appointee's date of birth	James C. Feliciano (ジェームス･フェリシアーノ): 22 September 1969. Gunji Kunihiro (軍司国弘), Kimura Takao (木村高男), Yamashita Koki (山下功起), Nishino Takeshi (西野武): Not disclosed
Name of departing officer	Chiku Kazuhiro (知久一博), Saito Junichi (齋藤淳一)
Former position of departing officer	Chiku Kazuhiro (知久一博): Statutory auditor. Saito Junichi (齋藤淳一): Executive officer (Director of 株式会社あすか製薬メディカル)
New position of departing officer	Chiku Kazuhiro (知久一博): Not disclosed. Saito Junichi (齋藤淳一): Retired
Whether the incumbent will remain in office	Chiku Kazuhiro (知久一博): Will not remain on the Board of Directors. Saito Junichi (齋藤淳一): Will not remain on the Board of Directors
Number of directors after the change	13 (including 7 outside directors)
Change in Corporate Governance Structure	The company plans to abolish the statutory auditor system and transition to a structure with directors who are Audit and Supervisory Committee Members.
Subject to Approval by the General Meeting of Shareholders	Yes. Changes in directors, including Audit and Supervisory Committee Members, are scheduled to be submitted as company proposals at the 5th Annual General Meeting of Shareholders scheduled for 24 June 2026.

Items this document does not state (7)

Year the appointee joined the CompanyNumber of shares held by the appointeeReason for departureReason for changeReasons for appointmentFiling as an independent officerDetails of organizational changes

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The changes in directors are scheduled to be submitted as company proposals at the Annual General Meeting of Shareholders scheduled for 24 June 2026, while the changes in executive officers are scheduled to be resolved at a Board of Directors meeting after the same meeting. No specific reasons for the individual changes are provided.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.

Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.

Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.